| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
48,040,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for cardiopulmonary diseases. Co.'s primary product candidate, bentracimab, is a reversal agent for the antiplatelet drug ticagrelor. Co. is developing its preclinical product candidate, PB6440, is an aldosterone synthase inhibitor being developed for treatment-resistant hypertension. Co.'s preclinical programs include: Glucagon-like peptide-2, which stimulates growth of intestinal villi, increasing their ability to absorb nutrients and C-type natriuretic peptide, which is a regulator of bone growth and can rescue defects in fibroblast growth factor 3.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
1,795,357 |
| Total Sell Value |
$0 |
$0 |
$0 |
$271,150 |
| Total People Sold |
0 |
0 |
0 |
2 |
| Total Sell Transactions |
0 |
0 |
0 |
2 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Humphries William D. |
Director |
– • – |
2023-05-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,538 |
2,538 |
|
- |
|
| Hutson Nancy J |
Director |
– • – |
2023-05-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,750 |
37,510 |
|
- |
|
| Van Den Broek Richard |
Director |
– • – |
2023-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
3,750 |
0 |
|
- |
|
| Thorp Clay |
Director |
– • – |
2023-05-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,750 |
36,693 |
|
- |
|
| Loewy Caroline M |
Director |
– • – |
2023-05-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,750 |
3,750 |
|
- |
|
| Sapir Alex |
Director |
– • – |
2023-05-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,750 |
3,750 |
|
- |
|
| Harrigan Edmund |
Director |
– • – |
2023-05-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,750 |
9,750 |
|
- |
|
| Baskett Forest |
10% Owner |
– – • |
2022-10-25 |
4 |
S |
$0.15 |
$262,264 |
D/D |
(1,784,109) |
4,857,525 |
|
- |
|
| Burkhardt Glen |
SVP of Human Resources |
• – – |
2022-05-23 |
4 |
AS |
$0.79 |
$8,886 |
D/D |
(11,248) |
0 |
|
- |
|
| Sharp John P |
Chief Financial Officer |
• – – |
2022-05-20 |
4 |
A |
$0.68 |
$4,106 |
D/D |
6,026 |
65,767 |
|
- |
|
| Burkhardt Glen |
SVP of Human Resources |
• – – |
2022-05-20 |
4 |
A |
$0.68 |
$7,663 |
D/D |
11,248 |
11,248 |
|
- |
|
| Arnold Susan Elizabeth |
SVP, Technical Operations |
• – – |
2022-05-20 |
4 |
A |
$0.68 |
$7,438 |
D/D |
10,917 |
41,236 |
|
- |
|
| Birchall Jonathan |
Chief Commercial Officer |
• – – |
2022-05-20 |
4 |
A |
$0.68 |
$13,626 |
D/D |
20,000 |
20,000 |
|
- |
|
| Mow Jonathan P |
Chief Executive Officer |
• • – |
2022-05-20 |
4 |
A |
$0.68 |
$7,438 |
D/D |
10,918 |
132,502 |
|
- |
|
| Hanson Kristopher |
SVP and General Counsel |
• – – |
2022-05-20 |
4 |
A |
$0.68 |
$3,291 |
D/D |
4,831 |
8,463 |
|
- |
|
| Burkhardt Glen |
VP, Human Resources |
• – – |
2021-11-19 |
4 |
AS |
$2.37 |
$13,665 |
D/D |
(5,766) |
0 |
|
- |
|
| Burkhardt Glen |
VP, Human Resources |
• – – |
2021-11-19 |
4 |
A |
$2.01 |
$11,590 |
D/D |
5,766 |
5,766 |
|
- |
|
| Sharp John P |
Chief Financial Officer |
• – – |
2021-11-19 |
4 |
A |
$2.01 |
$4,054 |
D/D |
2,017 |
59,741 |
|
- |
|
| Hutson Nancy J |
Director |
– • – |
2021-11-08 |
4 |
OE |
$3.15 |
$23,310 |
D/D |
7,400 |
33,760 |
|
- |
|
| Hutson Nancy J |
Director |
– • – |
2021-11-05 |
4 |
OE |
$2.26 |
$60,909 |
D/D |
26,360 |
26,360 |
|
- |
|
| Mow Jonathan P |
Chief Executive Officer |
• • – |
2021-11-03 |
4 |
OE |
$1.24 |
$24,800 |
D/D |
20,000 |
166,850 |
|
- |
|
| Sharp John P |
Chief Financial Officer |
• – – |
2021-11-03 |
4 |
OE |
$1.68 |
$12,600 |
D/D |
7,500 |
57,724 |
|
- |
|
| Mow Jonathan P |
Chief Executive Officer |
• • – |
2021-08-27 |
4 |
OE |
$1.24 |
$24,800 |
D/D |
20,000 |
146,850 |
|
- |
|
| Hutson Nancy J |
Director |
– • – |
2021-08-18 |
4 |
B |
$3.08 |
$9,240 |
I/I |
3,000 |
4,000 |
2.1 |
- |
|
| Thorp Clay |
Director |
– • – |
2021-08-18 |
4 |
B |
$3.00 |
$30,000 |
D/D |
10,000 |
32,943 |
2.39 |
- |
|
85 Records found
|
|
Page 1 of 4 |
|
|
